Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.48 |
| ▸ | NPY1R | P25929 | 8/20 | 0.48 |
| ▸ | NPY2R | P49146 | 6/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.48 |
| ▸ | TFPI | P10646 | 1/20 | 0.47 |
| ▸ | FURIN | P09958 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30148473 | 0.94 | FURIN (0.46) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL30148472 | 0.94 | TFPI (0.47) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL30874404 | 0.90 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL30124571 | 0.89 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL30208666 | 0.89 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL29967673 | 0.88 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29678407 | 0.88 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31467767 | 0.88 | NPY4R (0.53) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31343254 | 0.86 | TFPI (0.53) | TFPIFURINRXFP1 | |
| SCHEMBL30441875 | 0.85 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | PALATIN TECHNOLOGIES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459894-B2 | Orally active melanocortin receptor-4 compounds | MC4R, MC1R, MC3R | NPY4R 10/4885NPY1R 12/4885NPY2R 14/4885 |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | MC4R, MC1R, MC3R | NPY4R 10/4885NPY1R 12/4885NPY2R 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.